DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
CONTINUING DATA
This application is a CON of PCT/CN2022/130472 11/08/2022
FOREIGN APPLICATIONS
CHINA 202111448300.2 11/30/2021
Claims 1-8 are pending.
Claim Rejections - 35 USC § 103
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:
A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.
This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention.
Claim(s) 1-8 is/are rejected under 35 U.S.C. 103 as being unpatentable over CN113662955A (November 11, 2021, machine translation) in view of Terrago (Cell Metabolism 27, 1081-1095, May 1, 2018).
CN113662955A teaches that NAD supplementation ameloriates doxorubicin-induced cardiotoxicity. See abstract. Administration of NAD was by injection at 50 mg/kg/d. See page 3, first paragraph.
CN113662955A does not teach the administration of compound 78c.
Terrago teaches that the CD38 inhibitor 78c increased NAD+ levels. See Summary. Inhibition of CD38 promotes an increase in NAD+. See page 1, Highlights. 78c was administered by injection at a dose of 10 mg/kg/dose or 15 mg/kg/dose. See page e4, Drug Treatments.
It would have been obvious to one of ordinary skill in the art at the time the application was filed to administer 78c along with NAD in the CN113662955A method because the CN113662955A method relies upon supplementation with NAD to increase NAD+ levels and 78c also increases NAD+ in the body. The skilled artisan would have expected the combination to result in even higher levels of NAD+ in the body because each agent (NAD and 78c) increases NAD+. Simply combining the NAD injection and the 78c injection would have resulted in a ratio of 5:1 or 1:5, or a ratio of 1:3.33 or 3.33:1.
Figure 2 of the specification shows a greater increased level of NAD+ after administration of NAD and 78c compared to administration of NAD alone, but there is no evidence of record that the difference is not simply additive since 78c is known to increase NAD+ levels. "A greater than expected result is an evidentiary factor pertinent to the legal conclusion of obviousness... of the claims at issue." Evidence of a greater than expected result may also be shown by demonstrating an effect which is greater than the sum of each of the effects taken separately (i.e., demonstrating "synergism"). Merck & Co. Inc. v. Biocraft Laboratories Inc., 874 F.2d 804, 10 USPQ2d 1843 (Fed. Cir.), cert. denied, 493 U.S. 975 (1989). However, a greater than additive effect is not necessarily sufficient to overcome a prima facie case of obviousness because such an effect can either be expected or unexpected. Applicants must further show that the results were greater than those which would have been expected from the prior art to an unobvious extent, and that the results are of a significant, practical advantage. MPEP 716.02(a).
Conclusion
No claims are allowed.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to LAYLA D BERRY whose telephone number is (571)272-9572. The examiner can normally be reached 7:00-3:00 CST, M-F.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Scarlett Goon can be reached at 571-270-5241. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/LAYLA D BERRY/Primary Examiner, Art Unit 1693